Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM

Original Article from The New England Journal of Medicine — Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Read the full article here

Related Articles